Every Form 4 that Cardio Diagnostics Holdings Inc. (CDIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CDIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDIO filings page.
Cardio Diagnostics Holdings, Inc. (CDIO) director Wendy J. Betts received a direct award of 3,286 stock options on September 30, 2026. The options have an exercise price of $1.90 per share and expire September 30, 2036. Her directly held option position following the award was 15,656 shares.
Cardio Diagnostics Holdings, Inc. (CDIO) director Peter K. Fung received a grant of 3,286 stock options on September 30, 2026, to acquire common stock at an exercise price of $1.90 per share. After the grant, he directly held 15,656 stock options. The options expire on September 30, 2036.
Cardio Diagnostics Holdings, Inc. director James Intrater was granted 3,286 stock options on September 30, 2026. The options relate to Common Stock, carry an exercise price of $1.90 per share, and expire on September 30, 2036. His directly held stock-option position was 16,607 options following the grant.
Cardio Diagnostics Holdings, Inc. (CDIO) director Paul Frederick Burton was granted 3,286 stock options to buy Common Stock on September 30, 2026, at an exercise price of $1.90 per share. His reported direct total following the award was 16,607 options; they expire September 30, 2036.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options as part of his compensation. On June 30, 2026, he was awarded 2,854 stock options with a conversion price of $2.19 per share, each option representing the right to buy one share of common stock. These are classified as a grant or award, not an open-market purchase or sale. Following this award, Fung holds a total of 12,367 stock options linked to Cardio Diagnostics common stock, giving him additional potential future ownership if he chooses to exercise the options before they expire in 2036.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts received a grant of stock options covering 2,854 shares of common stock. The options have an exercise price of $2.19 per share and expire on June 30, 2036. This is a compensation-related award, not an open-market trade, and brings her directly held option awards to a total of 12,367 underlying shares.
Cardio Diagnostics Holdings director James Intrater received a new stock option grant as part of his compensation. On June 30, 2026, he was granted options to acquire 2,854 shares of common stock at an exercise price of $2.19 per share, expiring on June 30, 2036. After this award, he directly holds options for 13,318 shares in total.
Cardio Diagnostics Holdings director Burton Paul Frederick received a grant of stock options, providing additional equity-based compensation. The award covers 2,854 options to buy Common Stock at an exercise price of $2.19 per share, expiring on June 30, 2036. Following this grant, Frederick holds 13,318 stock options directly.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options for 3,205 shares of Common Stock at an exercise price of $1.95 per share on March 31, 2026. Following the grant, he holds stock options for a total of 9,513 shares, expiring on March 31, 2036.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts received a grant of stock options covering 3,205 shares of Common Stock. The options have an exercise price of $1.95 per share and expire on March 31, 2036. Following this award, she directly holds 9,513 stock options.
Intrater James reported acquisition or exercise transactions in this Form 4 filing.
Cardio Diagnostics Holdings director James Intrater received a grant of 3,205 stock options on Common Stock at $1.95 per share. These options were granted on March 31, 2026 and expire on March 31, 2036. Following the award, he holds 10,464 stock options directly.
Cardio Diagnostics Holdings director Burton Paul Frederick received a grant of stock options as compensation. He was awarded 3,205 options to buy Common Stock at an exercise price of $1.95 per share, expiring on March 31, 2036. Following this grant, he holds 10,464 derivative securities directly.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung reported receiving a grant of stock options. On 12/31/2025, he was awarded options to buy 2,306 shares of common stock at an exercise price of $2.71 per share. After this grant, he beneficially owns a total of 6,308 stock options directly. This filing records the equity compensation awarded to a board member and does not involve any sale of shares.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts reported a stock option grant. On December 31, 2025, she was awarded 2,306 stock options with a right to buy common stock at an exercise price of $2.71 per share. After this grant, she beneficially owns 6,308 derivative securities in the form of stock options, held with direct ownership.
Cardio Diagnostics Holdings, Inc. director Burton Paul Frederick reported a new stock option award. On 12/31/2025, he was granted 2,306 stock options (right to buy common stock) with a conversion or exercise price of $2.71 per share. After this grant, he beneficially owns 7,259 derivative securities in the form of stock options, held in direct ownership. The filing was made on Form 4 for a single reporting person, reflecting an option grant coded as an acquisition.